{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-23-000027","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.995814+00:00","generated_at":"2026-06-12T06:08:49.218634+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amneal Q2 revenue up 7% to $599M, net income $12M; raises 2023 guidance","bullets":["Q2 net revenue $599M, +7% YoY; GAAP net income $12M vs loss $121M prior year.","Adjusted net income $57M, adjusted EBITDA $146M (+9% YoY), adjusted diluted EPS $0.19.","Raising 2023 full year guidance following strong H1 performance.","Growth driven by Generics (complex portfolio, biosimilars), AvKARE expansion, and Specialty.","Company addressing U.S. drug shortages as one of largest domestic manufacturers."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-23-000027","json":"https://secwatch.observer/filing/0001723128-23-000027.json","markdown":"https://secwatch.observer/filing/0001723128-23-000027.md","text":"https://secwatch.observer/filing/0001723128-23-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/0001723128-23-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/amrx-20230804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T06:08:49.218634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"482d0e57b83e54c4c5dee4e5c0eb3f44ebcf3988","claim":"Amneal Pharmaceuticals, Inc. reported second quarter ended June 30, 2023 results: revenue $599 million, net income $12 million, EPS $0.08. Guidance raised.","evidence_excerpt":"AMNEAL REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS ‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Full Year Guidance ‒","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000027/0001723128-23-000027-index.htm","confidence":0.98,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Revenue","value":"$599 million"},{"label":"Net income","value":"$12 million"},{"label":"EPS","value":"$0.08"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}